	US 11,746,159 B2
	*Humanized anti-MUC1 antibodies**
Cynthia Bamdad, Waltham, MA (US); and Benoit Smagghe, Waltham, MA (US)
Assigned to MINERVA BIOTECHNOLOGIES CORPORATION, Waltham, MA (US)
Appl. No. 15/549,942
Filed by Minerva Biotechnologies Corporation, Waltham, MA (US)
PCT Filed Feb. 10, 2016, PCT No. PCT/US2016/017422 § 371(c)(1), (2) Date Aug. 9, 2017, PCT Pub. No. WO2016/130726, PCT Pub. Date Aug. 18, 2016.
Claims priority of provisional application 62/114,526, filed on Feb. 10, 2015.
Prior Publication US 2018/0112007 A1, Apr. 26, 2018
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/30 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/3092 (2013.01) [A61K 39/00117 (2018.08); A61K 2039/5156 (2013.01); A61K 2039/5158 (2013.01); C07K 2317/24 (2013.01); C07K 2317/34 (2013.01); C07K 2317/52 (2013.01); C07K 2317/622 (2013.01); C07K 2319/02 (2013.01); C07K 2319/30 (2013.01)]

13 Claims

1. A chimeric antigen receptor (CAR) comprising a scFv or humanized scFv of an MN-E6 scFv set forth as consisting of SEQ ID NOS: 233, 235, or 237, MN-C2 scFv set forth as consisting of SEQ ID NOS:239, 241, or 243, MN-C3 scFv set forth as consisting of SEQ ID NOS: 245, 247, or 249 or MN-C8 scFv set forth as consisting of SEQ ID NOS:251, 253, or 255.